NEW YORK (GenomeWeb) – Leerink Partners and Canaccord Genuity today initiated coverage of HTG Molecular Diagnostics. Leerink gave the firm's shares an "Outperform" rating and an $18 price target while Canaccord gave them a "Buy" rating with a $17 price target.

Canaccord analyst Mark Massaro said in a report that HTG has the opportunity to be a leading player in the approximately $27 billion molecular profiling market, especially for oncology, which he estimated was more than $15 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.